Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma

Reuters03-23
<a href="https://laohu8.com/S/PHIO">Phio Pharmaceuticals</a> reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma
  • Phio said Phase 1b results from its escalating-dose study of intratumoral PH-762 (NCT 06014086) in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma will be presented on March 28, 2026 at the American Academy of Dermatology Late-Breaking Research Session S034.
  • The company reported 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events.
  • Phio reported an approximately 65% pathological response rate in cutaneous squamous cell carcinoma across dosing cohorts, including 85% in the highest-dose cohort.
  • Mary Spellman is scheduled to present the data in a 12-minute podium session at 3:00 PM MDT in Denver, Colorado.
  • Phio said it plans FDA engagement on next-stage clinical development in Q2 2026 and reported cash runway into the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603230700NEWSFILECNPR____20260323_289479_1) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment